ArticleBMC infectious diseases2026
Bacterial profile, antimicrobial resistance patterns and associated factors among cancer patients at Hawassa University Comprehensive Specialized Hospital, Sidama region, Southern Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfectious diseases are the leading cause of morbidity and mortality among cancer patients due to impaired immunity and the immunosuppressive effect of cancer treatment. Therefore, the aim of this study was to determine the bacterial profile, antimicrobial resistance patterns, and factors associated among cancer patients at Hawassa University Comprehensive Specialized Hospital, Sidama region, Southern Ethiopia.
methodsA cross-sectional study was conducted on 266 bacterial infection suspected cancer patients from January 1 to June 30, 2024. Socio-demographic and clinical data were collected using a structured questionnaire. Blood, urine, sputum, and swab samples were collected and transported to the Sidama Region Public laboratory, microbiology laboratory for bacterial investigation. Biochemical and antimicrobial susceptibility testing was done using standard bacteriological techniques. Data were analyzed using SPSS version 28. Bivariate and multivariable logistic regression was done to assess associated factors and a p-value of < 0.05 with 95% CI were considered statistically significant.
resultOf the 266 samples cultured, 56 (21.1%) (95% CI = 16.2-25.9) were culture positive for bacterial infection. CoNS, 18 (32.1%) was the predominant isolate, followed by E. coli, 11 (19.6%) and K. pneumonia, 9 (16.1%). Gram-positive bacteria showed high resistance to nitrofurantoin, 23 (88.5%), tetracycline, and penicillin, 22 (84.6%) each. Similarly, gram negative bacteria showed high resistance to nitrofurantoin, 23 (76.7%) and tetracycline, 21 (70.0%). The overall prevalence of MDR organisms in this study was 46 (82.1%). All S. aureus and K. oxytoca isolates were MDR. Being a rural resident (AOR = 0.47; 95% CI = 0.237-0.918; P = 0.027), stage I cancer (AOR = 0.08; 95%CI = 0.007-0.884, P = 0.039) and patients with a cancer in progression, (AOR = 2.52; 95%CI = 1.011-6.298, P=0.047) were statistically associated with bacterial infection.
conclusionIn the current study, the prevalence of bacterial infection among cancer patients was high (21.1%). CoNS were the most dominant isolates among cancer patients. High resistance of the isolates to commonly used antibiotics; nitrofurantoin, tetracycline, and penicillin were observed. Rural residence, stage I cancer, and progressive cancer showed significant associations with bacterial infections in cancer patients. Thus, the treatment of cancer patient's bacterial infection should depend on an antimicrobial susceptibility test. Moreover, evaluation of bacterial infection risk factors and tracking of antibiotic resistance are crucial in the controlling of bacterial infection and drug resistance among cancer patients. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.